Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 37, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s13046-018-0702-x
Keywords
Next generation sequencing (NGS); Precision medicine; Genomic aberrations; Regulatory issues; Ethics; Patient advocacy; Bioinformatics; Cancer screening and prevention
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC Nuvenia Fellowship) [19503, 14204, 19052]
- EU project ULTRAPLACAD [633937]
- Regina Elena Scientific Direction
Ask authors/readers for more resources
The United States Food and Drug Administration (FDA) recently approved the clinical use of two comprehensive 'mid-size' Next Generation Sequencing (NGS) panels calling actionable genomic aberrations in cancer. This is the first endorsement, by a regulatory body, of a new standard of care in oncology. Herein, we argue that besides its many practice-changing implications, this approval tears down the conceptual walls dividing system biology from clinical practice, diagnosis from research, prevention from therapy, cancer genetics from cancer genomics, and computational biology from empirical therapy assignment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available